Elevated high-sensitivity C-reactive protein among apparently healthy adults with concomitant prediabetes and latent tuberculosis infection in Nigeria
DOI:
https://doi.org/10.18203/2320-6012.ijrms20210407Keywords:
Adults, Biomarker, Highly-Sensitive C-reactive protein, Latent tuberculosis infection, PrediabetesAbstract
Background: The increasing prevalence and convergence of type 2 diabetes mellitus (DM) and active tuberculosis (TB) comorbidity, especially in adults in the lower-and middle-income countries, demand new approaches to control the ‘syndemic’. Consequently, we set out to investigate the possibility of early detection of prediabetes mellitus and/or latent tuberculosis infection using novel method.
Methods: This was a case-control study of 105 adults classified into 4 groups: Healthy Community Controls (HCC, n=30); Prediabetes mellitus (PDM, n=25); Latent Tuberculosis Infection (LTBI, n=23); Individuals with Prediabetes mellitus+Latent Tuberculosis Infection (PDM+LTBI, n=27). Sera collected were assayed for high-sensitivity C-reactive protein (hs-CRP) using the ultra-sensitive Human high sensitivity C-reactive protein ELISA Kit (Melsin Medical Co., Ltd, China). Other ancillary tests and measurements done include Erythrocyte Sedimentation Rate, serum Glycated-hemoglobin (HbA1c), Interferon-gamma (INF-ϒ) and Waist circumference.
Results: A total of 88 (83.8%) of the enrolled participants had full complement of results and were included in the analysis of four study groups: HCC (n=25), PDM (n=21), LTBI (n=19) and PDM+ LTBI (n=23). With respect to the serum biomarkers, isolated PDM and LTBI cases recorded significantly higher HbA1c (%) and INF-ϒ positivity respectively. Predictors of PDM+LTBI show statistically significant higher tertile (T3), representing elevated hs-CRP levels, (OR=6.50, 95% CI=4.83-22.39, p=0.0037).
Conclusions: This study revealed that persons harboring the two associated asymptomatic conditions, PDM + LTBI have higher inflammatory state detectable by assaying the biomarker, hs-CRP, which could be used for ‘one-time bi-directional targeted screening’ for PDM in LTBI and vice versa.
Metrics
References
Al-Rifai RH, Pearson FG, Critchley JA, Abu-Rhadad LJ. Association between diabetes mellitus and active TB. A systematic review and meta-analysis. PLoS ONE 2017;12:eo187967.
Firanescu AG, Popa A, Sandu MM, Protasiewicz DA, Popa SG, Mota M. The global prevalence and incidence of diabetes mellitus and pulmonary tuberculosis. Roma J Diabetes Nutr Meta Dis. 2016;23(3):319-26.
Global Tuberculosis Control 2018, WHO, Geneva. Use of high burden country list for TB by WHO in post-2015 era. Available at https//www.who.int /tb/publications/global_report/en/.2018. Accessed on 04 March 2020.
Adeloye D, Ige JO, Aderemi AV, Adeleye N, Amoo EO, Auta A, Oni G . Estimating the prevalence, hospitalization and mortality from type 2 diabetes mellitus in Nigeria: a systematic review and meta-analysis. BMJ Open.
Chatterjee R, Narayan KMV, Lipscomb J and Phillips LS. Screening for diabetes and pre-diabetes should be cost-saving in patients at high risk. Diabetes Care. 2013;36(7):1981-7.
Baumeister D, Akhtar R, Ciufulini S, Pariante CM, Modelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour-necrosis factor-α. Mol Psychiatry. 2016;21:642-9.
Rekeneire N, Pelia R, Ding J, Colbert LH, Visser M, Shorr R et al. Diabetes, hyperglycemia,and inflammation in older individuals. The Health, Aging and body composition study. Diabetes Care. 2006;29:1902-8.
Pepys MB, Hirschfied GM. C-reactive protein. A critical update. J Clin Invest. 2003;111:180512
Meier-Ewert HK, Ridker P, Rifai N, Prick N, Dinger D, Mullington J. Absence of diurnal variation of C-reactive protein levels in healthy human subjects. Clin Chem. 2001:47:426-30.
Ehiaghe FA, Akinshipe BO, Ehiaghe IJ, Josiah S, Agbonlahor ED, Etikerentse M. The levels of C-reactive protein, malondialdehyde and absolute lymphocyte counts in pre and post-acute exercise. J Sports Med Doping Studies. 2017;7:188.
Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45:1563-9.
Azam M, Lestari S, Rahayu SR, Fibriana AI, Setianto B, Widyyastiti NS. et al. Baseline and post-exercise high-sensitivity c-reactive protein levels in endurance cyclists: The Indonesian north coast and Tour de Borobudur 2017. Study. Indones Biomed J. 2019;11(1):91-9.
Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001:47:444-50.
Ledue TB, Rifai N. High sensitivity immunoassays for C-Reactive protein: promises and pitfalls. clinical chemistry and laboratory Med. 2005;39(11):185
American Diabetic Association. Classification and diagnosis of diabetes: Standard medical care in diabetes. Diabetes Care. 2018;41:S13-S27.
Shin SH, Lee YJ, Lee YA, Kim JH, Lee SY, Shin CH. High-sensitivity C-Reactive protein is associated with prediabetes and adiposity in Korean Youth. Metabolic Syn Related Dis. 2020;18(1):47-55.
Dodig S, Galez D, Zoricic LI, Kristic KB, Kovac K, Nogalo B. C-Reactive protein and complement components C3 and C4 in children with latent tuberculosis infection. Biochemia Medica. 2008;1:52-8.
Effoe VS, Correa A, Chen A, Lacy ME and Bertoni AG. High-sensitivity c-reactive protein is associated with incident type 2 diabetes among African Americans: The Jackson Heart Study. Diabetes Care. 2015;38(9):1694-1700.
Sabanayagam C, Shankar A, Lim SC, Lee J, Tai ES, Wong TY. Serum C-reactive protein level and prediabetes in two Asian populations. Diabetologia. 2011;54:767-75.
Akinshipe BO, Ezeani PC, Digban KA, Ehiaghe FA, Adedeji EB, Ehiaghe JI. Immunodiagnostic potential of an in-vitro interferon-gamma release assay for latent tuberculosis infection among apparently healthy individuals in Okada Community, Nigeria. Int J Immunol. 2017;5(3):41-8.
Akinshipe BO, Yusuf EO, Akinshipe FO, Moronkeji MA, Nwaobi AC. Prevalence and determinants of pre-diabetes and latent tuberculosis infection among apparently healthy adults in three Communities in Southern Nigeria. Int J Immunol. 2019:7(2):23-32.
Ayah R, Joshi MD, Mutai KK, Wanjiru R. A population-based survey of prevalence of diabetes and correlates in an urban slum in Nairobi, Kenya. BMC Public Health. 2013;13:371.
Meme N, Amwayi S, Nganga Z, Buregyeya E. Prevalence of undiagnosed diabetes and pre-diabetes among hypertensive patients attending Kiambu district Hospital, Kenya: A cross-sectional study. Pan African Medi J. 2015;22:286.
Roche Cobas c111 User Manual. Available at https//www.scibd.com/doc/9125231/Roche-cobas c111-user-Manual. Accessed on 24 March 2020
Nigeria diabetes association guidelines 2018. Published by the Diabetes Association of Nigeria. Available at https//www.idf.org/ournetwork /regions-members/Africa. Accessed on 4 March 2020.
Nigeria National tuberculosis and leprosy and Buruli Ulcer control Program (NTLCP) National Strategic Plan-TB 2015-2020.
Quantiferon-TB Gold (in-tube method).Package insert.2013.Retrieved from Cellestis website. Available at http://www.Cellestis.com/IRM /company/show page.aspx (cpin-1171) Accessed on 19 December 2019
Human high sensitivity C-Reactive Protein (hs-CRP) ELISA KIT.CAT.NO: EKHU-1155’Package insert. May 2019. Melsin Medical Co, Limited, China.
Luna JM, Moon YP, Liu KM, Spitalnik S, Paik MC, Cheung K. High Sensitivity C-reactive protein and interleukin-6 dominant inflammation and ischemic stroke risk: The Northern Manhattan Study. Stroke. 2014;45(4):979-87.
Pfutzner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther. 2006:8(1):28-36.
Ehiaghe FA. Some physicochemical changes associated with type2 diabetes mellitus in Benin City, Nigeria.Int J Biol Chem Sci. 2015;9:2582-8.
Sarrinapakorn V, Wanicagool W. Association between hs-CRP and HbA1c in overweight type-2 diabetic female patients. J Med Assoc Thai. 2013;96(3):54-8.
Danesh J, Wheeler JG, Hirschfield GM, Eda S. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N Engl J Med. 2004;350:1387-97.
Downloads
Published
How to Cite
Issue
Section
